- Home
- EEA vs SERA Comparison
EEA vs SERA Comparison
Compare EEA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EEA | SERA |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 79.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EEA | SERA |
|---|---|---|
| Price | $9.68 | $1.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.5K | ★ 96.7K |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $875.93 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $8.11 | $1.37 |
| 52 Week High | $11.43 | $4.09 |
Technical Indicators
Market Signals| Indicator | EEA | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 33.07 | 40.13 |
| Support Level | N/A | $1.72 |
| Resistance Level | $11.02 | $2.00 |
| Average True Range (ATR) | 0.29 | 0.22 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 9.48 | 30.86 |
Price Performance
Historical ComparisonAbout EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.